Study guide

5.5 Oral Anticoagulants, Antiplatelets & Peri-Procedural Management

Registered Cardiac Electrophysiology Specialist RCES

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pre-Procedural Assessment & Patient Preparation

1.1 Procedure Room Preparation, Equipment Verification & Aseptic Readiness 1.2 Pre-Procedural Clinical Evaluation, Labs, Consents & The Universal Time-Out 1.3 Patient Identification, Transport, HIPAA & Procedural Documentation 1.4 Patient Monitoring Setup, Defibrillator Pads & Pre-Procedural CIED Interrogation 1.5 Vascular Access Planning, Skin Preparation & Sterile Draping

2 Chapter 2: Cardiac Anatomy, Conduction & Electrophysiologic Foundations

2.1 Cardiac Anatomy for the EP Lab: Chambers, Access Routes & Coronary Supply 2.2 The Cardiac Conduction System, Action Potentials & Ion Channel Physiology 2.3 Cardiac Vector Analysis, 12-Lead ECG Fundamentals & Axis Determination

3 Chapter 3: EP Lab Instrumentation, Connectology & Lab Safety

3.1 EP Recording System Architecture, Signal Amplification & Frequency Filters 3.2 Cardiac Stimulator Operation, Junction Box Routing & Noise Troubleshooting 3.3 Electrical Safety, Electrical Units, Electrocautery & Fire Safety 3.4 Radiation Safety Physics, ALARA Principles, Shielding & Dose Limits 3.5 Procedural Supplies, Catheter Inventory, Surgical Instrumentation & Wound Closure

4 Chapter 4: Intra-Procedural Imaging, Sedation & Physiologic Monitoring

4.1 Fluoroscopic Projections (RAO, LAO, AP) & X-ray Tube Optimization 4.2 Intracardiac Echocardiography (ICE) Principles, Views & Catheter Navigation 4.3 Non-Radiographic Imaging: Cardiac CT/MRI, Image Fusion & Ultrasound-Guided Access 4.4 Conscious Sedation Protocols, Airway Management & Hemodynamic Monitoring 4.5 Vital Signs, Normal Laboratory Values & Intra-Procedural Lab Monitoring

5 Chapter 5: EP Pharmacology, Anticoagulation & Emergency Drugs

5.1 Vaughan Williams Antiarrhythmic Classification & EP Electrophysiology 5.2 Diagnostic & Provocative Drugs: Adenosine, Isoproterenol, Epinephrine, Atropine 5.3 Sedation & Analgesia Pharmacology, Reversal Agents & Recovery Scoring 5.4 Heparin Protocol, ACT Monitoring & Emergency Reversal with Protamine 5.5 Oral Anticoagulants, Antiplatelets & Peri-Procedural Management 5.6 ACLS Algorithms & Emergency Medications in the EP Lab

6 Chapter 6: Catheter Navigation, Normal Electrograms & Baseline Intervals

6.1 Standard Diagnostic Catheter Positions & Fluoroscopic/Anatomical Landmarks 6.2 Intracardiac Electrogram Interpretation & Normal Baseline Intervals (PA, AH, HV) 6.3 His Bundle Electrogram Recording, Split His Potentials & Infranodal Conduction

7 Chapter 7: Programmed Electrical Stimulation & Refractory Periods

7.1 Pacing Stimulation Fundamentals, Capture Thresholds & Drive Trains 7.2 Refractory Period Determination (ERP, RRP, FRP) & Sinus Node Function Testing (SNRT, cSNRT) 7.3 AV Nodal Decremental Conduction & Dual AV Nodal Physiology

8 Chapter 8: Diagnostic Evaluation of Supraventricular & Ventricular Tachycardias

8.1 Narrow-Complex Tachycardias: Differential Diagnosis of AVNRT, AVRT & AT 8.2 Diagnostic Pacing Maneuvers: Entrainment, PPI-TCL, V-A-V vs V-A-A-V & His-Refractory PVCs 8.3 Wide-Complex Tachycardias & Ventricular Arrhythmia Mapping Criteria

9 Chapter 9: Bradyarrhythmias, AV Block & Atrial Arrhythmia Recognition

9.1 Bradyarrhythmias, AV Block Classification & Conduction System Disease 9.2 Atrial Fibrillation & Atrial Flutter: Classification, ECG Recognition & Stroke Risk

10 Chapter 10: 3D Electroanatomic Mapping & Ablation Biophysics

10.1 3D Electroanatomic Mapping Systems (Carto, EnSite, Rhythmia) Setup & Troubleshooting 10.2 Activation, Propagation & Bipolar Voltage Substrate Mapping 10.3 Ablation Biophysics: Radiofrequency, Cryoablation & Pulsed Field Ablation (PFA)

11 Chapter 11: Transseptal Access, Catheter Ablation Targets & Endpoints

11.1 Transseptal Puncture: Anatomy, Technique, Imaging Guidance & Complications 11.2 Catheter Ablation of AVNRT Slow Pathway & Accessory Pathways (WPW) 11.3 Cavotricuspid Isthmus (CTI) Ablation for Typical Atrial Flutter 11.4 Pulmonary Vein Isolation (PVI) for AFib & Ventricular Tachycardia Ablation

12 Chapter 12: Cardiac Implantable Electronic Devices: Implantation & Testing

12.1 Pacemaker & Transvenous ICD Implantation Techniques & Safety 12.2 Intra-Procedural Electrical Testing: Sensing, Pacing Thresholds, Impedance & DFT 12.3 Cardiac Resynchronization Therapy (CRT) & Conduction System Pacing (HBP, LBBAP)

13 Chapter 13: CIED Interrogation, Programming & Troubleshooting

13.1 NBG Pacemaker Codes, Pacing Modes & Timing Cycles 13.2 CIED Interrogation Workflow, Programmer Operation & Peri-Procedural Reprogramming 13.3 Interpreting & Conveying Interrogated Data: Diagnostics, Counters & Stored Episodes 13.4 Pacing & Sensing Malfunctions, Electromagnetic Interference & Temporary Pacing

14 Chapter 14: Specialized Devices, Extraction & Acute Procedural Emergencies

14.1 Subcutaneous ICD (S-ICD), Leadless Pacemakers & Left Atrial Appendage Closure 14.2 Transvenous Lead Extraction Tools, Techniques & Safety Precautions 14.3 Acute Procedural Emergencies: Perforation, Tamponade, Pericardiocentesis & Air Embolism

15 Chapter 15: Post-Procedural Care, Hemostasis & Complication Management

15.1 Femoral Hemostasis Techniques: Manual Compression, Figure-of-8 & Closure Devices 15.2 Post-Procedural Complications: Vascular Injury, AV Block, Esophageal Injury & Neurologic Deficits 15.3 Post-Procedural CIED Assessment, Device Follow-Up & Wound Care 15.4 Post-Procedure Patient Recovery, Discharge Education & Clinical Handover

5.5 Oral Anticoagulants, Antiplatelets & Peri-Procedural Management

Key Takeaways Explain This Topic AI

CHA2DS2-VASc assigns 2 points each for age 75 or older and prior stroke or TIA, and 1 point each for heart failure, hypertension, age 65-74, diabetes, vascular disease, and female sex.

Ablation is performed on uninterrupted warfarin with an INR of 2.0-3.0 or on a minimally interrupted DOAC, because interrupted anticoagulation with heparin bridging increases both bleeding and thromboembolism.

Idarucizumab reverses dabigatran and andexanet alfa reverses apixaban and rivaroxaban; four-factor prothrombin complex concentrate plus vitamin K reverses warfarin.

Anticoagulation continues for at least 2-3 months after ablation regardless of rhythm, and long-term continuation is decided by CHA2DS2-VASc rather than by procedural success.

A transesophageal echocardiogram or cardiac CT excludes left atrial appendage thrombus when anticoagulation has been subtherapeutic or interrupted before a left-sided procedure.

Last updated: September 2026

5.5 Oral Anticoagulants, Antiplatelets & Peri-Procedural Management

Intra-procedural heparin is only half of the anticoagulation picture. Patients arrive in the EP lab already taking an oral anticoagulant, an antiplatelet agent, or both, and the decisions made before the case begins drive both stroke risk and bleeding risk.

  • 1. Stroke and Bleeding Risk Scoring
  • CHA₂DS₂-VASc
  • Letter Factor Points
  • C Congestive heart failure / LV dysfunction 1
  • H Hypertension 1
  • A₂ Age ≥ 75 2
  • D Diabetes mellitus 1
  • S₂ Prior Stroke / TIA / thromboembolism 2
  • V Vascular disease (prior MI, PAD, aortic plaque) 1
  • A Age 65-74 1
  • Sc Sex category (female) 1
  • Maximum 9

The two 2-point items — age ≥ 75 and prior stroke/TIA — are the most commonly missed detail. Anticoagulation is generally recommended at a score of ≥ 2 in men and ≥ 3 in women, and considered at 1 and 2 respectively; female sex alone does not drive treatment.

Worked example. A 78-year-old woman with hypertension, diabetes, and a prior TIA: age ≥ 75 (2) + hypertension (1) + diabetes (1) + prior TIA (2) + female (1) = 7 . This is a high-risk patient in whom anticoagulation is not optional and in whom pre-procedural imaging matters if therapy has lapsed.

HAS-BLED

H ypertension (uncontrolled), A bnormal renal or liver function (1 each), S troke, B leeding history or predisposition, L abile INR, E lderly (> 65), D rugs (antiplatelets, NSAIDs) or alcohol (1 each) — maximum 9. A score ≥ 3 flags high bleeding risk. Critically, HAS-BLED identifies modifiable risk factors to correct; it is not a reason to withhold anticoagulation in a patient who needs it.

2. The Agents

Drug Class / target Onset Half-life Monitoring Renal clearance

Warfarin Vitamin K antagonist (factors II, VII, IX, X, protein C and S) 3-5 days for full effect 36-42 h INR 2.0-3.0 Hepatic

  • Dabigatran Direct thrombin (IIa) inhibitor 1-3 h 12-17 h None routine ~80% renal
  • Rivaroxaban Factor Xa inhibitor 2-4 h 5-13 h None routine ~33% renal
  • Apixaban Factor Xa inhibitor 3-4 h ~12 h None routine ~27% renal
  • Edoxaban Factor Xa inhibitor 1-2 h 10-14 h None routine ~50% renal

Two clinically load-bearing facts: warfarin's slow onset means it cannot be started and relied upon within days , and its early effect is paradoxically procoagulant because protein C falls before factor II. Dabigatran's heavy renal clearance means that in acute kidney injury its effect accumulates dramatically.

Antiplatelets: aspirin irreversibly inhibits COX-1 for the platelet's 7-10 day life; clopidogrel, prasugrel, and ticagrelor block the P2Y12 receptor (ticagrelor reversibly). Dual antiplatelet therapy plus an anticoagulant markedly increases bleeding and is minimized in duration wherever possible.

3. Peri-Procedural Strategy

The strategy differs by procedure type, and the exam tests the distinctions.

Catheter ablation of atrial fibrillation

Strategy Practice Evidence

Uninterrupted warfarin Continue through the procedure with INR 2.0-3.0 on the day Lower thromboembolism and lower major bleeding than bridged interruption

Uninterrupted or minimally interrupted DOAC Continue, or hold one dose the morning of the procedure and resume the same evening Comparable safety to uninterrupted warfarin

Heparin bridging after interruption Avoided Increases bleeding without reducing stroke

Intra-procedural heparin is given at or immediately before transseptal puncture with an ACT target of 300-350 seconds in the left atrium.

CIED implantation

The landmark finding here is counterintuitive and frequently tested: for patients at moderate-to-high thromboembolic risk, continuing warfarin through device implantation produces far fewer clinically significant pocket hematomas than interrupting it and bridging with heparin . Bridging is therefore avoided. DOACs are commonly held for one to two doses around implantation depending on renal function and bleeding risk.

Pre-procedural imaging

A transesophageal echocardiogram (or cardiac CT) is obtained before left atrial ablation or LAA closure when anticoagulation has been interrupted, subtherapeutic, or of uncertain duration; when atrial fibrillation has persisted beyond 48 hours without documented anticoagulation; or when thromboembolic risk is high. A detected appendage thrombus cancels the procedure and mandates several weeks of therapeutic anticoagulation with repeat imaging.

Renal dosing

DOAC dose reduction depends on creatinine clearance and drug-specific criteria — apixaban is reduced when two of three are present (age ≥ 80, weight ≤ 60 kg, creatinine ≥ 1.5 mg/dL), and dabigatran is contraindicated at severely reduced clearance. A patient whose renal function has deteriorated since the last clinic visit may be far more anticoagulated than the chart suggests.

4. Reversal

Agent Reversal Notes

Warfarin Vitamin K (slow, hours) plus 4-factor prothrombin complex concentrate (immediate) Fresh frozen plasma is an alternative when PCC is unavailable, at a large volume cost

Dabigatran Idarucizumab — a monoclonal antibody fragment Rapid and specific; dialysis also removes dabigatran

Apixaban / rivaroxaban Andexanet alfa — a modified decoy factor Xa 4-factor PCC is used when andexanet is unavailable

Unfractionated heparin Protamine sulfate , 1 mg per 100 units of active heparin Slow IV; anaphylactoid risk with NPH insulin exposure, prior vasectomy, or fish allergy

Low molecular weight heparin Protamine, partial reversal only (~60%) Anti-Xa activity is incompletely neutralized

  • Antiplatelets No specific reversal Platelet transfusion for life-threatening bleeding
  • 5. After the Procedure

The post-ablation rule is one of the most reliably tested facts in EP:

Anticoagulation continues for a minimum of 2 to 3 months after ablation regardless of the rhythm on the monitor. The ablated atrium is denuded and inflamed, and post-cardioversion atrial stunning impairs mechanical function even when electrical sinus rhythm is restored.

Beyond that window, continuation is decided by CHA₂DS₂-VASc , not by whether the ablation appears successful. A patient with a score of 4 who is in sinus rhythm at three months still requires anticoagulation, because asymptomatic recurrence is common and the score reflects underlying stroke risk.

Patients frequently ask to stop therapy once symptoms resolve; the correct counselling is that symptom resolution is not evidence of arrhythmia elimination.

After left atrial appendage closure , a device-specific regimen — anticoagulation or dual antiplatelet therapy for a defined interval, followed by imaging to confirm seal and absence of device-related thrombus, then a step-down to aspirin — replaces indefinite anticoagulation.